Verdinexor

Drug Profile

Verdinexor

Alternative Names: KPT-335

Latest Information Update: 03 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Karyopharm Therapeutics
  • Class Antivirals; Hydrazines; Pyridines; Small molecules; Triazoles
  • Mechanism of Action Exportin-1 protein inhibitors; Nuclear export inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Viral infections

Most Recent Events

  • 16 Mar 2017 Karyopharm Therapeutics has patent protection for verdinexor in USA
  • 20 May 2015 Karyopharm Therapeutics announces intention to submit IND to the US FDA in the year 2015
  • 20 May 2015 Karyopharm Therapeutics plans a phase I trial in Healthy volunteers in USA (PO) (NCT02431364)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top